By the 2023 fiscal year, 23andMe had reported a net loss of $312 million and its individual share price has plummeted a staggering 98% since going public.

The DNA-testing company is exploring its options, including a business combination and the sale of some or all of its assets.

Me is considering a sale of the company as it weighs up strategic options, capping a torrid year for the genetic testing business. A special committee of its directors’ board is considering various directions for the company in addition to a sale,